Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: a preliminary study. 2002

A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
Department of Biochemical Oncology, Cancer Institute (WIA), Regional Cancer Center for Cancer Research and Treatment of Govt of India, Adyar, Madras-600020, India. meenakshi_a3@rediffmail.com

Monoclonal antibody CIBCgp185 of IgG2a isotype has been generated against C-erbB-2 oncoprotein using BT474 breast carcinoma cell line as immunogen. Earlier studies have revealed that this MAb has potential application as diagnostic tool in the detection of breast cancers overexpressing C-erbB-2. In the present study, the reactivity pattern of this MAb was studied on frozen sections of 28 malignant and 15 normal breast tissues and on cultured mammary tumor cell lines by indirect immunofluorescent staining. Results indicated that gp185C-erbB-2 was overexpressed in 6 malignant specimens, indicating correlation with immunohistochemical analysis studied previously. These results indicate that immunofluorescence might also be used to study C-erbB-2 overexpression in breast cancers and could serve as a confirmatory test for IHC. However, further studies with large number of cases are needed to confirm these results.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D018719 Receptor, ErbB-2 A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. HER-2 Proto-Oncogene Protein,Proto-Oncogene Protein HER-2,Proto-Oncogene Protein p185(neu),c-erbB-2 Protein,erbB-2 Proto-Oncogene Protein,erbB-2 Receptor Protein-Tyrosine Kinase,neu Proto-Oncogene Protein,Antigens, CD340,CD340 Antigen,Erb-b2 Receptor Tyrosine Kinases,Metastatic Lymph Node Gene 19 Protein,Neu Receptor,Oncogene Protein HER-2,Proto-Oncogene Proteins c-erbB-2,Proto-oncogene Protein Neu,Receptor, Neu,Receptors, erbB-2,Tyrosine Kinase-type Cell Surface Receptor HER2,p185(c-neu),p185erbB2 Protein,CD340 Antigens,Erb b2 Receptor Tyrosine Kinases,ErbB-2 Receptor,HER 2 Proto Oncogene Protein,Oncogene Protein HER 2,Proto Oncogene Protein HER 2,Proto Oncogene Proteins c erbB 2,Proto-Oncogene Protein, HER-2,Proto-Oncogene Protein, erbB-2,Proto-Oncogene Protein, neu,Tyrosine Kinase type Cell Surface Receptor HER2,c erbB 2 Protein,erbB 2 Proto Oncogene Protein,erbB 2 Receptor Protein Tyrosine Kinase,erbB-2 Receptors,neu Proto Oncogene Protein
D019084 Fluorescent Antibody Technique, Indirect A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) Immunofluorescence Antibody Test, Indirect,Immunofluorescence Technique, Indirect,Fluorescent Antibody Technic, Indirect,Immunofluorescence Technic, Indirect,Indirect Fluorescent Antibody Technic,Indirect Fluorescent Antibody Technique,Indirect Immunofluorescence,Indirect Immunofluorescence Assay,Assay, Indirect Immunofluorescence,Assays, Indirect Immunofluorescence,Immunofluorescence Assay, Indirect,Immunofluorescence Assays, Indirect,Immunofluorescence Technics, Indirect,Immunofluorescence Techniques, Indirect,Immunofluorescence, Indirect,Immunofluorescences, Indirect,Indirect Immunofluorescence Assays,Indirect Immunofluorescence Technic,Indirect Immunofluorescence Technics,Indirect Immunofluorescence Technique,Indirect Immunofluorescence Techniques,Indirect Immunofluorescences

Related Publications

A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
January 1994, Oncology,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
March 1991, British journal of cancer,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
April 1989, Cancer research,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
November 1996, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
August 1992, Clinical chemistry,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
August 1993, International journal of cancer,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
June 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
May 1992, Zhonghua zhong liu za zhi [Chinese journal of oncology],
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
November 1991, Journal of clinical pathology,
A Meenakshi, and R Suresh Kumar, and N Siva Kumar, and V Ganesh
January 1997, Anticancer research,
Copied contents to your clipboard!